Syndax Pharmaceuticals Inc

SNDX

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001395937

SEC filings (opens in a new tab)

In the last 90 days, Syndax Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 242 institutions reported holding it in 13F filings for Q2 2026, worth $2.36B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026: $843.9M
Insider buysOpen market, last 90 days: 0
Insider sellsLast 90 days, $113.7K in total: 1
13F holdersQ2 2026, −2 vs. previous quarter: 242
13F valueReported value at the end of Q2 2026: $2.36B
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $172.4M; +627.8% year over year
Net income, FY2025: -$285.4M; No comparable prior period
Free cash flow, FY2025: -$323.2M; No comparable prior period
Revenue, Q3 FY2026: $83.3M; +81.6% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $285.4M (165.6% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 18.9M; Shares sold short
Change: +918.5K; +5.1% vs. previous
Days to cover: 6.41; At average daily volume

Superinvestors holding SNDX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding SNDX at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Syndax Pharmaceuticals Inc insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Oct 30, 2026 (view filing)7:09 PM ET	Oct 29	1 day	Podlesak DennisDirector	SSale	−8.00K	$14.21	−$113.7K	−3.2%239.8K after	10b5-1
Jul 9, 2026 (view filing)4:54 PM ET	Jul 8	1 day	Metzger Michael AChief Executive Officer	SSale	−32.4K	$24.24	−$784.8K	−6.3%484.8K after	10b5-1
Jun 12, 2026 (view filing)	Jun 11-12	1 day	Botwood Nicholas A.J.Head of R&D, CMO	SSale	−65.5K	$18.07	−$1.18M	−51.8%60.9K after	2 lots10b5-1
Jun 2, 2026 (view filing)	Jun 1	1 day	Goldan Keith A.Chief Financial Officer	SSale	−1.18K	$18.99	−$22.4K	−0.8%139.3K after
Jun 2, 2026 (view filing)	Jun 1	1 day	Metzger Michael AChief Executive Officer	SSale	−6.85K	$18.99	−$130.0K	−1.4%484.8K after
Feb 10, 2026 (view filing)	Feb 9	1 day	Metzger Michael AChief Executive Officer	SSale	−17.2K	$21.03	−$360.9K	−3.4%491.7K after
Feb 10, 2026 (view filing)	Feb 9	1 day	Goldan Keith A.Chief Financial Officer	SSale	−3.41K	$21.03	−$71.7K	−2.4%140.4K after
Feb 6, 2026 (view filing)	Feb 6	Same day	Metzger Michael AChief Executive Officer	SSale	−7.41K	$20.62	−$152.8K	−1.4%508.8K after
Feb 6, 2026 (view filing)	Feb 6	Same day	Goldan Keith A.Chief Financial Officer	SSale	−2.08K	$20.62	−$42.9K	−1.4%143.8K after
Sep 8, 2025 (view filing)	Sep 8	Same day	Metzger Michael AChief Executive Officer	SSale	−157.3K	$16.41	−$2.58M	−34.5%298.7K after	10b5-1

Top 10 13F holders, Q2 2026

See all 242 holders

The largest institutional positions in Syndax Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding SNDX in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
BlackRock, Inc.	9,020,006	$197.2M	0.00%	+765,580+9.3%	Added
Kynam Capital Management, LP	8,050,959	$176.0M	9.73%	00.0%	Unchanged
Goldman Sachs Group Inc	5,861,265	$128.1M	0.01%	+864,478+17.3%	Added
State Street Corp	5,658,424	$123.7M	0.00%	+1,228,348+27.7%	Added
Bank of America Corp	4,045,094	$88.4M	0.01%	−204,742−4.8%	Reduced
Vanguard Capital Management LLC	3,927,892	$85.9M	0.00%	+105,313+2.8%	Added
Deerfield Management Company, L.P. (Series C)	3,779,900	$82.6M	0.86%	00.0%	Unchanged
Eversept Partners, LP	2,798,210	$61.2M	3.33%	−87,412−3.0%	Reduced
Geode Capital Management, LLC	2,584,136	$56.5M	0.00%	+427,078+19.8%	Added
Hood River Capital Management LLC	2,564,279	$56.1M	0.41%	+209,994+8.9%	Added

Holders of 5% or more of SNDX

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Syndax Pharmaceuticals Inc.

Largest holders of SNDX from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Kynam Capital Management, LP	13G/A	9.98%8.52M shares	–	Feb 14, 20242 filings	Feb 14, 2025	SEC
BlackRock, Inc.	13G/A	7.80%6.74M shares	–	Oct 21, 20244 filings	Apr 17, 2025	SEC
Goldman Sachs Group Inc	13G/A	6.50%5.58M shares	+1.30 ppfrom 5.20%	Feb 12, 20253 filings	Aug 13, 2025	SEC
State Street Corp	13G	5.20%4.65M shares	−1.20 ppfrom 6.40%	Feb 6, 20236 filings	Nov 10, 2026	SEC
Vanguard Capital Management LLC	13G	5.05%4.46M shares	New	Apr 30, 20261 filing	Apr 30, 2026	SEC